Mersana Therapeutics Appoints Dirk Huebner, M.D., as Chief Medical Officer
“We are excited for Dirk to join Mersana and bring his deep experience in the field of ADC clinical development. Dirk’s direct experience in the European approval and label expansion activities supporting ADCETRIS® (brentuximab vedotin) will help us build on our leading clinical development organization and prepare for the next steps in the development of XMT-1536 and XMT-1522,” said Anna Protopapas, President and Chief Executive Officer of Mersana. “We believe this deep experience will also accelerate our ability to develop our growing ADC pipeline as we move forward on our Dolaflexin, Dolasynthen and Alkymer platforms.”
“I’m pleased to join Mersana at a time of important growth for the company,” said Dr. Huebner. “Mersana’s innovative platforms, robust discovery efforts and promising clinical programs hold tremendous promise to address significant unmet patient needs. I am looking forward to working with such a noteworthy and experienced leadership team and working with the company to bring innovative new medicines to patients.”
Prior to joining Mersana, Dr. Huebner served as Vice President, Head of Development, for Boston Biomedical, where he built a robust clinical development team and oversaw the clinical development of several early stage compounds. Prior to that, he spent six years at Takeda Oncology as Executive Medical Director. During Dr. Huebner’s tenure at Takeda Oncology, he served as the global clinical lead for ADCETRIS® (brentuximab vedotin), an ADC that treats select types of lymphoma. In that role, he led the regulatory approval of ADCETRIS in
Investor & Media Contact
Source: Mersana Therapeutics, Inc.